uniQure Submits AMT-130 for U.S. and U.K. Review

Company: uniQure · Drug: Ifezuntirgene Inilparvovec (AMT-130) · Indication: Huntington’s Disease · Regulatory Action: BLA (U.S.) + MAA (U.K.) Submitted · Date: September 2, 2026 Summary uniQure submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of ifezuntirgene inilparvovec,…